Epileptic Encephalopathy clinical trials at UCSF
8 in progress, 5 open to eligible people
Epileptic encephalopathy is a condition where seizures affect a child's development and brain function. UCSF is running clinical trials for new treatments. These trials test the safety and effectiveness of medicines like XEN496 and LP352 in children and adults with KCNQ2-DEE and other forms of the condition. The goals are to find better therapies and improve quality of life.
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
open to eligible people ages 1 month to 6 years
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).
San Francisco, California and other locations
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
open to eligible people ages 12-65
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
San Francisco, California and other locations
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
open to eligible people ages 2-21
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
San Francisco, California and other locations
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
open to eligible people ages 12-65
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
San Francisco, California and other locations
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
open to eligible people ages 1 month to 6 years
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
San Francisco, California and other locations
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Sorry, in progress, not accepting new patients
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
San Francisco, California and other locations
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Subjects With SCN8A-DEE
Sorry, accepting new patients by invitation only
Extension Study to Evaluate how safe and tolerable the drug NBI-921352 is when used as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
San Francisco, California and other locations
Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
Sorry, in progress, not accepting new patients
This is a multicenter, prospective, 2-year observational study in infants and children with developmental and epileptic encephalopathies (DEEs). The DEE currently being investigated is SCN1A-positive Dravet Syndrome.
San Francisco, California and other locations
Last updated: